Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient

Stephen J. Tomlanovich and Flavio Vincenti
CJASN March 2007, 2 (2) 198-199; DOI: https://doi.org/10.2215/CJN.00340107
Stephen J. Tomlanovich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flavio Vincenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

The introduction of new immunosuppression drugs in the 1990s resulted in marked reduction in acute rejection but had no appreciable impact on long-term graft survival. A major impediment to the improvement of long-term outcome has been attributed to the inexorable and progressive nephrotoxicity associated with the use of calcineurin inhibitors (CNI).

With the introduction of sirolimus in transplantation, it was hoped that its lack of nephrotoxicity in animal models would be translated in humans to improve immunosuppression with minimal effect on renal function. However, the results of the US Multicenter Trial with cyclosporine and sirolimus revealed that sirolimus-treated patients had significantly higher serum creatinine values at 6 and 12 mo despite a significant reduction in acute rejection rates (1). Further investigations proposed a pharmacokinetic interaction between sirolimus and cyclosporine to enhance tissue concentration of cyclosporine, augmenting its inherent nephrotoxic potential rather than a direct nephrotoxic effect of sirolimus (2). This clinical finding led to trials of sirolimus with cyclosporine minimization or withdrawal to address this combination-induced toxicity (3).

Another twist in the story occurred when reports of sirolimus causing the prolonged recovery of delayed graft function after renal transplantation were published (4,5). The initial belief in the renal transplant community that sirolimus was not nephrotoxic led to its use in delayed graft function to bridge the gap of immunosuppression until a CNI could be safely introduced. Another report described an example of cast nephropathy developing in the setting of delayed graft function (6). An animal model revealed a specific renal injury resulting in protein overload nephropathy and intratubular cast formation (7). It has been proposed that sirolimus impairs tubular epithelial cell regeneration through its effect on mammalian target of rapamycin (mTOR) and possibly via cell cycle arrest and apoptosis, thereby leading to delayed recovery of renal function in some patients.

Again, with the primary belief that sirolimus lacked inherent nephrotoxicity, clinicians began to use sirolimus to withdraw or minimize CNI exposure in patients with chronic renal insufficiency due to CNI nephrotoxicity or chronic transplant nephropathy. In addition, reports in animal models suggested that sirolimus, through its antiproliferative and anti-VEGF effects, might cause certain types of tumors to regress, and reports of sirolimus introduction causing the remission of Kaposi’s sarcoma in transplant patients led to the use of sirolimus replacing CNI in patients with different tumor types (8). Unfortunately, recent papers have described an increase in proteinuria in some patients converted from CNI to sirolimus for these indications (9–12). These studies suggest that the proteinuria increases primarily in patients with preexisting proteinuria (baseline values ranging from 0.3 to >1.0 g/d) or in the presence of advanced glomerular lesions. However, some patients had minimal proteinuria at baseline and subsequently developed nephrotic range proteinuria. This increased proteinuria has been attributed to the loss of CNI-mediated vasoconstriction, increased glomerular permeability, and proximal tubular cell injury caused directly or indirectly by sirolimus binding to albumin. Some papers described incompletely characterized de novo glomerular lesions as well as, in some cases, de novo FSGS-like lesions (13,14).

A case report described 12 g of proteinuria within 10 d of transplantation that resolved after the withdrawal of sirolimus (15). The renal biopsy did not reveal a glomerular lesion and the authors proposed a tubular injury leading to a decrease in tubular protein absorption as an explanation for the proteinuria. Another paper described proteinuria developing in patients on sirolimus and low-dose tacrolimus after islet cell transplantation (16). The patients may have had diabetic nephropathy (only one patient had a renal biopsy) predisposing them to progressive proteinuria. However, the proteinuria resolved after discontinuation of sirolimus, which suggests a direct effect of the drug.

Transplant immunosuppressive medications have been frequently utilized off-label in many types of both primary and secondary forms of glomerulonephritis. An animal model of the accelerated experimental model of membranous nephropathy demonstrated beneficial effects of sirolimus on tubulointerstitial inflammation, interstitial fibrosis, and compensatory renal hypertrophy (17). However, Fervenza et al. reported that six of 11 patients developed acute renal failure after the introduction of sirolimus for various types of glomerulonephritis (18). Unlike mycophenolate mofetil, sirolimus has not yet been embraced by the nephrology community for the treatment of immune-mediated glomerular diseases.

These accumulated clinical and scientific data suggest that sirolimus has inherent nephrotoxicity in certain circumstances. The cause of this nephtotoxicity is completely different from the mechanism of CNI-induced nephrotoxicity. In this issue of CJASN, Letavernier et al. have characterized the FSGS lesion developing in patients receiving sirolimus de novo or after conversion from CNI (19). This paper is the first to characterize both the histopatholgical as well as the immunohistochemical changes in patients developing proteinuria after exposure to sirolimus. The investigators provide convincing data to directly implicate sirolimus in podocyte dysregulation, thereby leading to the classic lesion of de novo FSGS. Sirolimus may mediate this process via a decrease in vascular endothelial growth factor or through its effect on mTOR to decrease cell survival. The development of nephrotic-range proteinuria was relatively uncommon, and the patients affected were exposed to relatively high levels of sirolimus. It is not clear that these patients had higher levels than the other 255 patients receiving sirolimus who did not develop the FSGS lesion. There were no apparent distinguishing features in the affected patients to predict who might be at risk for developing this infrequent complication. It is encouraging that the proteinuria resolved after sirolimus withdrawal. However, none of the patients had repeat biopsies to determine whether the changes in podocytes were reversed. This report should alert clinicians to monitor urinary protein in patients on sirolimus on a regular basis and consider discontinuation of the drug if the proteinuria is substantial and progressive.

Sirolimus has been a drug looking for a dominant role in immunosuppression regimens. Up to this point its long-term use has been limited by its profound effect on hematopoeisis as well as lipid metabolism in some patients. We must now add proteinuria to the list of complications that clinicians must consider when either using sirolimus de novo or for conversion in patients with CNI nephrotoxicity.

Disclosures

Drs. Vincenti and Tomlanovich receive research grants from Bristol-Myers Squibb, Novartis, Astellas Pharma US, Genentech, Iconix, Wyeth Pharmaceuticals, Pfizer, Roche, and Isotechnika.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

    See the related article, “High Sirolimus Levels May Induce Focal Segmental Glomerulosclerosis De Novo,” on pages 326–333.

  • Copyright © 2007 by the American Society of Nephrology

References

  1. ↵
    Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicenter study. The Rapamune US Study Group. The Lancet356 :194– 202,2000
    OpenUrl
  2. ↵
    Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou T-C, Kahan B: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol12 :1059– 1071,2001
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmax S, Hayry P, Neylan JF; for the Rapamune Maintenance Regimen Trial: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant4 :953– 961,2004
    OpenUrlCrossRefPubMed
  4. ↵
    McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant3 :416– 423,2003
    OpenUrlCrossRefPubMed
  5. ↵
    Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R: A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant14 :550– 554,2000
    OpenUrlCrossRefPubMed
  6. ↵
    Smity KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE, Polissar N, Davis CL: Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol14 :1037– 1045,2003
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Coombes JD, Mreich E, Liddle C, Rangan GK: Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int68 :2599– 2607,2005
    OpenUrlCrossRefPubMed
  8. ↵
    Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med352 :1317– 1323,2005
    OpenUrlCrossRefPubMed
  9. ↵
    Letavernier E, Pe’raldi M-N, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation80 :1198– 1203,2005
    OpenUrlCrossRefPubMed
  10. Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant21 :488– 493,2006
    OpenUrlCrossRefPubMed
  11. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant21 :3252– 3257,2006
    OpenUrlCrossRefPubMed
  12. ↵
    van den Akkher JM, Wetzels JFM, Hoitsma AJ: Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int70 :1355– 1357,2006
    OpenUrlCrossRefPubMed
  13. ↵
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostang L: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant20 :2517– 2523,2005
    OpenUrlCrossRefPubMed
  14. ↵
    Skhiri H, Morelon E, Noel L-H, Mamzer-Bruneel M-F, Legendre C, Peraldi M-N, Kreis H: Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transplant Int8 :458– 460,2005
    OpenUrl
  15. ↵
    Straathof-Galema L, Wetzels JFM, Dijkman DBPM, Steenbergen EJ, Hilbrands LB: Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant6 :429– 433,2006
    OpenUrlCrossRefPubMed
  16. ↵
    Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AMJ: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant5 :2318– 2323,2005
    OpenUrlCrossRefPubMed
  17. ↵
    Bonegio RGB, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol16 :2063– 2072,2005
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA; for the Mayo Nephrology Collaborative Group. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant10 :1288– 1292,2004
    OpenUrl
  19. ↵
    Letavernier E, Bruneval P, Mandet C, Duong Van Huyen J-P, Pe’raldi M-N, Helal I, Noel L-H, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol2 :326– 333,2007
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 2, Issue 2
March 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient
Stephen J. Tomlanovich, Flavio Vincenti
CJASN Mar 2007, 2 (2) 198-199; DOI: 10.2215/CJN.00340107

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Sirolimus: Defining Nephrotoxicity in the Renal Transplant Recipient
Stephen J. Tomlanovich, Flavio Vincenti
CJASN Mar 2007, 2 (2) 198-199; DOI: 10.2215/CJN.00340107
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
  • Should We Let Dialysis Patients Eat Their Fruits and Veggies?
Show more Editorials

Cited By...

  • Up-regulated mTOR Pathway Indicates Active Disease in Both Human Native and Transplant Kidneys
  • Nephrotic Range Proteinuria: Rare Manifestation of Scleroderma Renal Crisis
  • Google Scholar

Similar Articles

Related Articles

  • High Sirolimus Levels May Induce Focal Segmental Glomerulosclerosis De Novo
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire